BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Paradigms Foundation - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Paradigms Foundation
X-ORIGINAL-URL:https://paradigms.foundation
X-WR-CALDESC:Events for Paradigms Foundation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240611T153000
DTEND;TZID=Europe/Paris:20240611T163000
DTSTAMP:20240521T144907Z
CREATED:20240404T124944Z
LAST-MODIFIED:20240521T144907Z
UID:8839-1718119800-1718123400@paradigms.foundation
SUMMARY:Live webinar on the use of generic\, biosimilar and non-biologic complex drugs for multiple sclerosis
DESCRIPTION:Register now! \n\n\n\nJoin this valuable and instructive webinar!  \n\n\n\nFamiliarise yourself with the robust European regulatory processes and effective oversight for generic\, biosimilar\, and follow-on non-biologic complex drugs (NBCDs) of disease modifying therapies in multiple sclerosis that allow you to have informed conversations with your patients about the potential use of these agents. \n\n\n\nRegister now to gain insights from experts and ultimately optimize MS treatment strategies and improve patient outcomes! \n\n\n\n\nREGISTER\n\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration.  \n\n\n\nThe session will be held in English (translation in Spanish) on June 11th from 3:30 PM to 4:30 PM CEST. \n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation \n\n\n\n\n\n\n\nWhy participate? \n\n\n\n\n\nLearn about the regulatory requirements for generics\, biosimilars and follow-on NBCD’s in Europe.\n\n\n\nUnderstand the clinical considerations for generics\, biosimilars and follow-on NBCD’s in multiple sclerosis. \n\n\n\n\n\nWho should join? \n\n\n\nNeurologists who deal with multiple sclerosis (MS) treatment and management. Nurses working in the field of multiple sclerosis and patient representatives are also welcome to register.  \n\n\n\n\n\n\n\nAbstract \n\n\n\nBecause multiple sclerosis (MS) usually has an onset in early adulthood and is a progressive disease\, the economic burden is substantial\, and disease-modifying treatments (DMTs) constitute a large proportion of healthcare costs. The use of generic versions (of synthetic drugs)\, biosimilars (for biologics) or follow-on versions of non-biologic complex drugs (NBCDs) can reduce the overall cost of MS care and improve patient access. \n\n\n\nIn Europe\, there are robust regulatory processes and effective oversight for generic\, biosimilar and follow-on NBCDs of DMTs so that these agents can be considered interchangeable with the originator product. Physicians caring for patients with MS need to familiarise themselves with the evidence so that they can have informed conversations with their patients about the potential use of these agents. \n\n\n\n\n\n\n\nOUR SPEAKERS \n\n\n\n\n\n\n\nCelia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid and Professor of Neurology at the University Complutense\, Madrid\, Spain. \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest\, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As a principal investigator\, she has participated in more than 30c MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. \n\n\n\nBesides her clinical and research endeavors\, Professor Oreja-Guevara has held leadership roles in several neurology-focused organizations and academic societies\, such as the Demyelinating Diseases Group and the Neuroimaging Group of the Spanish Neurological Society. Professor Oreja-Guevara is also Co-Chair of the Multiple Sclerosis Panel of the European Academy of Neurology (EAN)\, and serves as an expert for the European Medicines Agency (EMA) and the Spanish Agency of Medicines and Medicinal Products\, highlighting her pivotal role in advancing neurology. \n\n\n\nConflict of Interest Form – Celia Oreja-Guevara\n\n\n\n\n\n\n\nThomas Berger\, Professor of Neurology and Chair of the Dept. of Neurology at the Medical University of Vienna.  \n\n\n\nThomas Berger\, MD\, MSc\, FEAN\, is Professor of Neurology and Chair of the Dept. of Neurology as well as Chair of the Comprehensive Center for Clinical Neurosciences & Mental Health at the Medical University of Vienna\, Austria.Scientific interests regard neuroimmunology\, especially inflammatory demyelinating CNS disorders with a dedicated focus on body-fluid and imaging biomarker research in multiple sclerosis\, NMOSD and MOGAD. \n\n\n\nConflict of Interest Form – Thomas Berger\n\n\n\nModerator: Stefaan De Corte\, General Manager\, ParadigMS \n\n\n\n\n\n\n\nREGISTRATION \n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n\nREGISTER\n\n\n\n\n\n\nPlease note: this is a live webinar primarily for neurologists from Europe\, the Middle-East and North-Africa. Should you not fit this category and should we reach maximum capacity (100)\, we might cancel your registration. \n\n\n\n\n\n\n\nOUR SPONSOR \n\n\n\nThis webinar is organised with the financial support of Sandoz. Sandoz was not involved in the elaboration of the presentations.
URL:https://paradigms.foundation/event/live-webinar-on-the-use-of-generics-biosimilars-and-nbcds-for-multiple-sclerosis/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/05/LAU-PROD-banner-live-webinar-sessions-1200x627px.jpg
END:VEVENT
END:VCALENDAR